Nephros, Inc. (NASDAQ:NEPH – Get Rating) – Equities research analysts at B. Riley boosted their FY2022 EPS estimates for shares of Nephros in a research note issued to investors on Thursday, November 3rd. B. Riley analyst M. Wiesenberger now forecasts that the company will earn ($0.49) per share for the year, up from their prior estimate of ($0.51). The consensus estimate for Nephros’ current full-year earnings is ($0.49) per share. B. Riley also issued estimates for Nephros’ Q4 2022 earnings at ($0.06) EPS.
Nephros Stock Performance
Shares of NEPH opened at $1.03 on Monday. The firm’s 50 day moving average price is $1.12 and its two-hundred day moving average price is $1.65. The firm has a market cap of $10.63 million, a P/E ratio of -1.39 and a beta of 1.34. Nephros has a twelve month low of $0.91 and a twelve month high of $8.15.
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently made changes to their positions in the stock. Bard Associates Inc. lifted its stake in Nephros by 7.0% during the 2nd quarter. Bard Associates Inc. now owns 263,754 shares of the company’s stock valued at $404,000 after acquiring an additional 17,346 shares in the last quarter. Cantor Fitzgerald L. P. bought a new stake in Nephros in the 1st quarter worth approximately $56,000. Wexford Capital LP lifted its position in Nephros by 0.4% in the first quarter. Wexford Capital LP now owns 3,663,969 shares of the company’s stock valued at $533,734,000 after purchasing an additional 13,440 shares during the last quarter. Renaissance Technologies LLC bought a new stake in Nephros in the first quarter valued at approximately $89,000. Finally, Elkhorn Partners Limited Partnership increased its stake in shares of Nephros by 56.0% during the first quarter. Elkhorn Partners Limited Partnership now owns 23,712 shares of the company’s stock valued at $104,000 after buying an additional 8,512 shares during the period. Institutional investors own 41.59% of the company’s stock.
Nephros Company Profile
Nephros, Inc develops and sells high performance water solutions to the medical and commercial markets in the United States. The company operates in three segments: Water Filtration, Pathogen Detection, and Renal Products. It offers ultrafiltration products that are used in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate; and in hospitals for the prevention of infection from waterborne pathogens, such as legionella and pseudomonas, as well as in military and outdoor recreation, commercial, and other healthcare facilities.
- Get a free copy of the StockNews.com research report on Nephros (NEPH)
- After Doubling, First Solar May Keep Shining
- Barrick Gold is a Hold as Long as Gold Prices Stay Stagnant
- MarketBeat: Week in Review 10/31-11/4
- Is Hershey’s a Sweet Stock to Buy After a Post-Earnings Dip?
- Datadog Doesn’t Belong In The Doghouse
Receive News & Ratings for Nephros Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nephros and related companies with MarketBeat.com's FREE daily email newsletter.